The purpose of this study is to determine whether acarbose therapy can reduce
cardiovascular-related morbidity and mortality in patients with impaired glucose tolerance
(IGT) who have established coronary heart disease (CHD) or acute coronary syndrome (ACS). A
secondary objective of the study is to determine if acarbose therapy can prevent or delay
transition to type 2 diabetes mellitus (T2DM) in this patient population.